dm+d
Unassigned
New Medicines
Acute bacterial skin and skin structure infections (ABSSI)
Information
New molecular entity
Not Known
Innovation Pharmaceuticals
Development and Regulatory status
None
None
Phase II Clinical Trials
Category
First-in-class a synthetic, defensin-mimetic. Directly lyses the bacterial cell membrane by penetrating into it and disrupting the barrier and membrane-associated metabolic functions, leading to bacterial death.
Skin and soft tissue infections (SSTIs) are common, and complicated SSTIs (cSSTIs) are the more extreme end of this clinical spectrum, encompassing a range of clinical presentations such as deep-seated infection, a requirement for surgical intervention, the presence of systemic signs of sepsis, the presence of complicating co-morbidities, accompanying neutropenia, accompanying ischaemia, tissue necrosis, burns and bites. Staphylococcus aureus is the commonest cause [2]
Acute bacterial skin and skin structure infections (ABSSI)
Intravenous